Aviado · Research
Longevity Daily
Wednesday, October 14, 2026
Listen
Today's Brief
GLP-1 drugs are making a serious case as anti-aging medications: Lilly's 700-person Surmount V trial — today's must-read — shows measurable biological age reductions after 72 weeks, not just weight loss. A KFF Health News investigation delivers a direct warning: BPC-157 and other podcast-hyped peptides are causing real harm, with patient stories being suppressed under MAHA's medical freedom push. A seven-trial meta-analysis quietly punctures vitamin D's longevity credentials, while Aviado breaks down why methylcobalamin B12 is the hidden engine of DNA repair. Harvard's rapamycin dog trial rounds out an edition packed with actionable findings.
10 stories6 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Brain Insulin Resistance May Be Alzheimer's Missing Link — and GLP-1 Drugs Could Fix It
A clinical review in Psychiatric Times maps how brain insulin resistance disrupts the mTOR/PI3K/Akt signaling pathway central to Alzheimer's pathology — and finds that both the Mediterranean diet and GLP-1 receptor agonists can restore normal function. The mechanism matters: when insulin signaling in the brain fails, it triggers the same molecular cascade implicated in amyloid plaque and tau tangle formation. If you're already tracking GLP-1 news for metabolic reasons, the dementia-prevention angle deserves serious attention.
Read more →Creatine May Shield the Brain From Gut Inflammation — Not Just Build Muscle
A rat study found that creatine supplementation largely prevented the hippocampal damage — neuron loss, inflammation, and disrupted electrical activity — caused by chronic gut inflammation in unsupplemented controls. The brain-gut axis is increasingly central to cognitive aging research, and this is one of the first studies to implicate creatine as a protective agent in that pathway. Important caveat: this is animal research, and human trials haven't yet tested this specific mechanism at established creatine doses.
Read more →Supplements & Compounds
B12's Real Job Isn't Preventing Anemia — It's Powering Your DNA Repair
Most people take B12 for energy or to avoid deficiency, but methylcobalamin — B12's active form — is the critical engine of the methionine cycle, which funds all DNA repair in your cells. Clinical data consistently shows B12 supplementation drops homocysteine by 2–4 μmol/L, but only when adequate folate and B6 are present — making those cofactors non-negotiable parts of any stack. If you're vegetarian, older, or have digestive issues, 500 mcg of methylcobalamin daily (not cheaper cyanocobalamin) is worth prioritizing.
Read the full Aviado analysis →People Are Getting Hurt by BPC-157 — and Their Stories Are Being Silenced
A KFF Health News investigation documents real patients experiencing serious, lasting side effects from BPC-157 — including months of fatigue, anxiety, and muscle twitching after just three days of intranasal use — a peptide drug popularized by longevity and "body optimization" podcasts. Under MAHA's medical freedom push, adverse event reports are getting little traction, leaving other users uninformed of documented risks. This is a direct warning for longevity-focused readers who may have encountered BPC-157 recommendations online: the evidence base is thin, and the harm reports are mounting.
Read more →Vitamin D Doesn't Move Key Longevity Biomarkers, Seven-Trial Meta-Analysis Finds
A meta-analysis pooling seven randomized controlled trials found that vitamin D supplementation fails to significantly alter irisin (the exercise-linked longevity hormone) or SIRT1 (a key longevity protein), despite promising signals from animal research. Many longevity optimizers supplement vitamin D expecting downstream effects on these pathways — this data says that's not happening in humans. The finding doesn't undermine vitamin D's role in bone health or immunity, but it substantially weakens the case for high-dose supplementation targeting longevity biomarkers specifically.
Read more →Research & Papers
GLP-1 Drugs Show Measurable Biological Age Reductions in 700-Person Human Trial
Fresh data from Lilly's Surmount V trial — a randomized 72-week study of more than 700 overweight adults — showed that both tirzepatide and semaglutide produced meaningful reductions in biological age, not just bodyweight, when presented at the Aging Research and Drug Discovery conference in Boston. The lead researcher noted it's "a significant reduction," even if it won't shave off decades — suggesting GLP-1 drugs could soon be positioned as the first broadly available anti-aging medications backed by real human trial evidence. This shifts the GLP-1 story considerably: the endpoint is no longer the scale, it's aging itself. For anyone following longevity pharmacology, this is the headline story of the week.
Read more →Scientists Erase a Century of Cellular Aging in Blood Cells From 101-Year-Olds
Researchers successfully reprogrammed blood cells from donors as old as 101 years into induced neural stem cells using just two transcription factors — SOX2 and cMYC — effectively erasing over a century of accumulated cellular aging in approximately 50 days. The study demonstrates that even extremely aged human cells retain remarkable biological plasticity, a finding with major implications for regenerative medicine and cell therapy targeting age-related neurological conditions. This is pre-clinical work, but the centenarian-age donor cohort makes it a standout proof-of-concept in the cellular reprogramming field.
Read more →Harvard's Rapamycin Dog Trial Could Fast-Track Human Longevity Research Within Five Years
Harvard researchers are enrolling dogs in a clinical trial testing whether rapamycin delays the onset of age-related disease — and because dogs age so rapidly, the team expects meaningful results in as little as five years. Dogs are uniquely valuable longevity models: they share our environment, diet, and chronic disease patterns far more closely than lab mice do. Positive outcomes would provide the strongest real-world platform yet for accelerating rapamycin trials in humans.
Read more →Lifestyle & Nutrition
Your Gut Microbiome Starts Aging Against You as Early as Your Mid-30s
A new literature review of human microbiome studies finds that gut composition begins shifting unfavorably — with pro-inflammatory species crowding out beneficial metabolite producers — as early as the mid-30s, far earlier than most people assume. Centenarians and supercentenarians consistently show distinct microbiome profiles compared to average older adults, underscoring the gut as a genuine and modifiable longevity variable. The practical takeaway: targeted microbiome strategies through diet, fiber, and probiotics deserve serious attention well before you reach 60 — or even 40.
Read more →Industry & Policy
Longevity Sector's $8.5B Bet Hinges on Whether FDA Accepts 'Biological Age' as a Clinical Endpoint
The longevity sector raised $8.49 billion in 2024 — more than double its 2023 total — and a significant fraction of that capital depends on whether the FDA will accept proteomic biological age scores (multi-protein plasma composites) as valid clinical trial endpoints. These biomarker signatures are now appearing as primary or secondary endpoints in prospective trials, a regulatory first for the aging field. If the FDA greenlights them, it could unlock approval pathways for dozens of longevity drugs currently stalled without an accepted measure of efficacy.
Read more →